Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
- 1 September 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 40 (46) , 3771-3778a
Abstract
Aims : Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding. The aim of this study was to estimate the individual lifetime treatment benefit and harm of adding low-dose rivaroxaban to aspirin in patients with stable cardiovascular disease. Methods and results : Patients with established CVD from the COMPASS trial (n = 27 390) and SMART prospective cohort study (n = 8139) were used. Using the pre-existing lifetime SMART-REACH model for recurrent CVD, and a newly developed Fine and Gray competing risk-adjusted lifetime model for major bleeding, individual treatment effects from adding low-dose rivaroxaban to aspirin in patients with stable CVD were estimated, expressed in terms of (i) life-years free of stroke or myocardial infarction (MI) gained; and (ii) life-years free from major bleeding lost. Calibration of the SMART-REACH model for prediction of recurrent CVD events in the COMPASS study was good. The major bleeding risk model as derived in the COMPASS trial showed good external calibration in the SMART cohort. Predicted individual gain in life expectancy free of stroke or MI from added low-dose rivaroxaban had a median of 16 months (range 1–48 months), while predicted individualized lifetime lost in terms of major bleeding had a median of 2 months (range 0–20 months). Conclusion : There is a wide distribution in lifetime gain and harm from adding low-dose rivaroxaban to aspirin in individual patients with stable CVD. Using these lifetime models, benefits and bleeding risk can be weighed for each individual patient, which could facilitate treatment decisions in clinical practice.Keywords
Funding Information
- Bayer AG
- University Medical Center Utrecht
This publication has 27 references indexed in Scilit:
- 2016 European Guidelines on cardiovascular disease prevention in clinical practiceEuropean Heart Journal, 2016
- How to translate clinical trial results into gain in healthy life expectancy for individual patientsBMJ, 2016
- An International Model to Predict Recurrent Cardiovascular DiseaseThe American Journal of Medicine, 2012
- AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 UpdateCirculation, 2011
- Estimating treatment effects for individual patients based on the results of randomised clinical trialsBMJ, 2011
- Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch databaseBMJ, 2010
- Cause-Specific Cumulative Incidence Estimation and the Fine and Gray Model Under Both Left Truncation and Right CensoringBiometrics, 2010
- Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosisEuropean Heart Journal, 2010
- Patients Enrolled in Large Randomized Clinical Trials of Antiplatelet Treatment for Prevention After Transient Ischemic Attack or Ischemic Stroke Are Not Representative of Patients in Clinical PracticeStroke, 2009
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005